U.S. increases its order for anthrax vaccine BioThrax

Emergent BioSolutions, Inc., recently announced that it has agreed to a modification of its current procurement contract to supply BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration, to the United States government.

The Maryland-based biopharmaceutical will now supply an additional 3.42 million doses of the vaccine beginning in the third quarter of 2011.

The contract modification is valued at up to $101 million for the delivery and shipment of the additional doses, which will begin immediately after the completion of the final delivery of the original 14.5 million doses specified in the original contract. Emergent BioSolutions, Inc., expects to complete all of the deliveries in 2011.

“Emergent proudly supports the U.S. government’s efforts and unwavering commitment to meet its stated need of 75 million doses of anthrax vaccines,” Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions, Inc., said. “This contract is an indication that BioThrax remains a critical component of the government’s arsenal of biodefense medical countermeasures. In addition to this contract modification, we are continuing discussions with the U.S. government regarding a follow-on procurement contract, which we anticipate will cover a multi-year period."

Over 42 million doses of BioThrax have been delivered to the U.S. government to date. Since 1998, over 10 million doses of BioThrax have been administered to more than 2.5 million military personnel.